50 Breast Tissue Differentiation With High Wavenumber Raman Spectroscopy for Future Intraoperative Margin Analysis

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 37-38

Thomas J.E. Hubbard, PhD1,2; Alexander P. Dudgeon, PhD2; C Murray; Douglas J. Ferguson1,2; Angela C. Shore1,2; Nicholas Stone1,2

1Royal Devon and Exeter Hospital, Exeter, UK

2University of Exeter Medical School, Exeter, UK

Background

Accurate intraoperative margin analysis (IMA) would reduce the need for surgical re-excision in breast-conserving surgery (BCS). High-wavenumber Raman spectroscopy (HWN RS) is a vibrational spectroscopy highly sensitive to changes in the protein and lipid environment and water content–biochemical differences found between tumor and normal breast tissue. We determined the diagnostic accuracy of a HWN RS system to differentiate between tumor and nontumor breast tissue for future IMA.

Materials and Methods

Thawed fresh-frozen human breast specimens were obtained with ethical approval from the Exeter Clinical Research Facility Tissue Bank (CRF Ref: CRF320; Tissue bank ethics number 16/ SC/0162). Paired biopsy specimens of tumor and nontumor tissue were measured with a handheld probe with a 785 nm laser excitation and a spectrometer with an indium-gallium-arsenide, or InGaAs, camera. Sections from specimens underwent histopathological diagnosis and Raman microspectrometry measurement with a Renishaw inVia system. Spectra were analyzed with a principal component analysis (PCA)–fed linear discriminant analysis (LDA) model, with leave-one-out-cross-validation (LOOCV) and calculation of the water/total HWN area ratio (W/TAR); a diagnostic threshold was determined by receiver operating characteristic curve analysis from a binomial logistic regression with k-fold 5 cross-validation.

Results

Ninety-six patients were included (invasive ductal carcinoma, n = 64; invasive lobular carcinoma, n = 21; ductal carcinoma in situ, n = 3; other carcinoma, n = 8). Matching of histopathology to HWN microspectrometry Raman spectra confirmed the spectral differences between tumor (protein, water-rich) and nontumor (lipid-rich, water-poor) tissue. Handheld probe spectra PCA analysis revealed the changes in protein, lipid, and water content were predominant spectral features, accounting for greater than 95% variance. The LDA analysis demonstrated an accuracy of 93.2% (sensitivity 93.8%; specificity 92.7%), and W/TAR analysis with a diagnostic threshold of 0.66 gave an overall accuracy of 92.2% (sensitivity 94.8%; specificity 89.6%) for differentiating between tumor and nontumor tissue. Diagnostic accuracy was unaffected by tissue staining with patent blue dye for concurrent sentinel lymph node biopsy, indicating its potential for intraoperative analysis.

Conclusions

We present an emerging technology that can differentiate between tumor and nontumor breast tissue with 93.2% accuracy. This system has the potential to provide IMA in BCS and reduce re-excision rates.

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients
Related Content